Related Experiment Videos
[Gene therapy perspectives in cystic fibrosis]
A T Midro1, L L Kulczycki, A Sledziewski
1Zakład Genetyki Klinicznej Instytutu Połoznictwa i Chorób Kobiecych Akademii Medycznej, Białymstoku.
Postepy Higieny I Medycyny Doswiadczalnej
|January 1, 1993
Summary
Cystic fibrosis (CF) is a genetic disease caused by CFTR gene mutations. Gene therapy, including adenovirus and retrovirus vectors, shows promise for treating CF by restoring chloride channel function.
Area of Science:
- Genetics
- Molecular Biology
- Biochemistry
Context:
- Cystic fibrosis (CF) is a common autosomal recessive genetic disorder.
- The CFTR gene, located on chromosome 7q31, encodes the cystic fibrosis transmembrane conductance regulator protein.
- The Delta F508 mutation is the most prevalent mutation, disrupting chloride transport.
Purpose:
- To review the understanding of the basic biochemical defect in CF.
- To explore current and potential therapeutic strategies for CF, including gene therapy.
- To discuss the advancements in gene transfer technologies for CF treatment.
Summary:
- The cystic fibrosis transmembrane conductance regulator (CFTR) functions as a glycoprotein and a chloride channel, regulated by phosphorylation and ATP binding.
- The Delta F508 mutation impairs CFTR function, leading to epithelial cell dysfunction and the pathology of CF.
- Gene therapy approaches, utilizing adenovirus and retrovirus vectors for CFTR gene transfer, are being investigated for CF treatment.
Impact:
- Understanding the CFTR protein and its mutations provides insight into the molecular basis of CF.
- Gene therapy offers a potential curative approach for CF, complementing pharmacologic treatments.
- Further research and safety evaluations are necessary before human clinical trials can commence for gene-based therapies.